Atlas Venture Opportunity Fund II, L.P. has filed a Form 144 to sell 4,942 shares of Disc Medicine, Inc., a company involved in pharmaceutical preparations. This move is significant as it may indicate a strategic shift in the fund's investment strategy and could influence the dynamics within the pharmaceutical industry.
Background
Atlas Venture Opportunity Fund II, L.P. is a limited partnership based in Cambridge, Massachusetts, with a focus on venture capital investments. The company is not publicly traded and primarily engages in investing in innovative companies across various sectors. The recent filing was made on October 19, 2026, and is part of a series of filings by the fund.
What the Filing Says
The Form 144 indicates that Atlas Venture Opportunity Fund II plans to sell 4,942 shares of Disc Medicine, Inc., which is listed under the SEC file number 001-39438. The aggregate market value of the shares to be sold is approximately $280,903.28. The shares were originally acquired through a private placement on May 1, 2020.
Impact
This sale could affect various stakeholders, including current and potential investors in Disc Medicine, Inc., as well as competitors in the pharmaceutical preparations sector. The filing suggests that Atlas Venture is actively managing its investment portfolio, which may lead to shifts in investor confidence and market dynamics.
What's Next
The filing does not specify what happens next regarding the sale of these shares or any further actions by Atlas Venture Opportunity Fund II.